Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments close on Thursday 25 April at 4:30pm because of system upgrades. We expect to open them again on Friday 26 April at 8am the latest.

A novel, safe and resistance-free treatment

Reference number
Coordinator GEDEA BIOTECH AB - Medicon Village
Funding from Vinnova SEK 1 000 000
Project duration June 2018 - April 2019
Status Completed

Purpose and goal

The purpose and aim of the project was to clinically validate the safety and efficacy of Gedea´s vaginal tablet in the treatment of vaginal fungal infections. This has been studied in a clinical trial with 24 patients. In parallel, we also examined in a separate clinical study the effect of treating bacterial vaginosis in 24 patients. Safety and efficacy have been confirmed. Additionally, the user experience during treatment has been investigated. In focus groups, the patient journey for patients with vaginal infections has been mapped.

Expected results and effects

The project has, as expected, provided us with information on the safety, clinical effect and user experience when treating vaginal fungal infections and bacterial vaginosis with Gedea’s vaginal tablet. Furthermore, we have performed focus group surveys with patients affected by vaginal infections. The focus groups have provided us with good knowledge about the patient journey and decisions taken by the patients and will serve as a basis for decisions during the development and for future marketing of the product. Thus, the expected outcome of the project has been fulfilled.

Planned approach and implementation

We have conducted two clinical studies of the effect of the vaginal tablet, on the treatment of vaginal fungal infections and on the treatment of bacterial vaginosis. The studies have been carried out at a total of four private gynecology clinics in Skåne and in collaboration with the Clinical Trial Unit, Region Skåne. In addition to safety, treatment results and user experience, the effect of the treatment on the vaginal microbiome will also be analyzed after the study has ended. The patient journey has been mapped through focus group surveys with women who had vaginal infections.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2018-00275

Page statistics